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Abstract: Background: To test the feasibility of benchmarking the care of women with pregnancies
complicated by hyperglycaemia. Methods: A retrospective audit of volunteer diabetes services
in Australia and New Zealand involving singleton pregnancies resulting in live births between
2014 and 2020. Ranges are shown and compared across services. Results: The audit included
10,144 pregnancies (gestational diabetes mellitus (GDM) = 8696; type 1 diabetes (T1D) = 435; type
2 diabetes (T2D) = 1013) from 11 diabetes services. Among women with GDM, diet alone was
used in 39.4% (ranging among centres from 28.8–57.3%), metformin alone in 18.8% (0.4–43.7%), and
metformin and insulin in 10.1% (1.5–23.4%); when compared between sites, all p < 0.001. Birth was
by elective caesarean in 12.1% (3.6–23.7%) or emergency caesarean in 9.5% (3.5–21.2%) (all p < 0.001).
Preterm births (<37 weeks) ranged from 3.7% to 9.4% (p < 0.05), large for gestational age 10.3–26.7%
(p < 0.001), admission to special care nursery 16.7–25.0% (p < 0.001), and neonatal hypoglycaemia
(<2.6 mmol/L) 6.0–27.0% (p < 0.001). Many women with T1D and T2D had limited pregnancy
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planning including first trimester hyperglycaemia (HbA1c > 6.5% (48 mmol/mol)), 78.4% and 54.6%,
respectively (p < 0.001). Conclusion: Management of maternal hyperglycaemia and pregnancy
outcomes varied significantly. The maintenance and extension of this benchmarking service provides
opportunities to identify policy and clinical approaches to improve pregnancy outcomes among
women with hyperglycaemia in pregnancy.
Keywords: gestational diabetes mellitus; healthcare benchmarking; audit; pregnancy; type 1 diabetes
mellitus; type 2 diabetes mellitus; pregnancy outcomes; HbA1c
1. Introduction
Hyperglycaemia in pregnancy is a growing problem worldwide [1], posing significant
risk to women and their pregnancies [2,3]. In Australia, more than one in 10 pregnancies
are complicated by hyperglycaemia [4]. The risks of hyperglycaemia and related adverse
pregnancy outcomes are greater among women of Indigenous background, and those born
outside Australia [4,5]. Adverse events remain high in pregnancies complicated by dia-
betes [4–7], suggesting insufficient pre-pregnancy preparation and antenatal management.
Profound urban–rural disparities [6] and variation in obstetric care across Australia [8]
limit access to optimal care for many women. Similar risks and variation exist in New
Zealand, with higher rates of gestational diabetes mellitus (GDM) and type 2 diabetes
(T2D) in pregnancy among Māori and Pacific people [9].
Mapping variations in antenatal diabetes care is an important tool for improving the
quality of care provided. A national audit and benchmarking program using standardised
criteria was found to be useful for identifying aspects of pre-pregnancy and antenatal care
needing improvement among women with diabetes [10], including the need for systemic
change [11,12]. A national audit and benchmarking process is currently lacking in Australia
for pregnancy care however is available outside of pregnancy [13]. In 1999, the Australasian
Diabetes in Pregnancy Society (ADIPS) proposed a national diabetes in pregnancy clinical
audit program to lead to the establishment of an internal audit and benchmarking pro-
cess. Subsequently, a pilot audit conducted in 2003 showed the feasibility of a large-scale
audit, but without funding, the approach was not sustainable [14]. The main objective
of this current pilot was to develop a sustainable dataset for pregnancies complicated by
hyperglycaemia, and to assist the development of a national clinical benchmarking and
audit program.
2. Materials and Methods
2.1. Participants
This multicentre pilot audit was conducted under the governance of ADIPS. All
diabetes in pregnancy services across Australia and New Zealand, including those from
tertiary, rural, indigenous, public, and private settings were eligible to participate in
the pilot program. All members of ADIPS were invited to participate by the ADIPS
secretariat via email, website, and forums. Other health facilities were open for participation
upon approaching the Secretariat. Our target for the pilot was to include 10 centres from
diverse settings. The benchmarking centre was located in a metropolitan city with a
large multiethnic population and had expertise from prior benchmarking analyses outside
of pregnancy. The benchmarking centre also volunteered to be one of the pilot sites.
Pregnancies in women with GDM, type 1 diabetes (T1D), or T2D resulting in live births
between years 2014 and 2020 were eligible for inclusion in the audit. Data from women
with multiple pregnancies or pregnancies ending in miscarriage, induced abortion, or
stillbirth were excluded from the audit because of variations in sources.
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2.2. Development of the Audit Tool
The audit tool was built upon the data set used previously [14], and the outcome
variables were defined according to the International Association of the Diabetes and
Pregnancy Study Groups’ consensus guidelines [15]. The audit tool was created in Excel
and discussed at the 2019 ADIPS annual scientific meeting. The data items were further
discussed using a Delphi process [16] and agreed to by the ADIPS Diabetes and Pregnancy
Audit Working Group consisting of 17 specialists across Australia and New Zealand. The
audit tool consisted of 55 items. Of those, 20 were core data items related to pregnancy plan-
ning and management to compare quality of pregnancy care against key recommendations
in the ADIPS guidelines [17] (Table 1).
Table 1. ADIPS key recommendations that were audited for women with diabetes [17].
No Best Practice Recommendations for Women with Diabetes
1 All pregnancies should be intended pregnancies.
2 Pre-pregnancy counselling regarding risks should be provided.
3 Teratogenic medications should be avoided before conception and during pregnancy.
4 Blood glucose should be near normal before conception and during pregnancy.
5 Women should receive high dose (2.5–5 mg daily) folate supplementation starting 3 months prior to conception until 12 weeks gestation.
6 Oral hypoglycaemic agents should be reviewed prior to conception.
7 First antenatal visit should occur early in pregnancy, before 8 weeks of gestation.
8 Glycaemic control should be balanced against the risk of hypoglycaemia in early pregnancy.
9 Women with diabetes should be monitored for signs or progression of diabetes microvascular complications.
10 Vaginal birth should be encouraged unless there are obstetric or fetal indications for caesarean section.
11 Breastfeeding should be encouraged for all women with diabetes.
ADIPS = Australasian Diabetes in Pregnancy Society.
The core data elements were complemented by demographic, treatment, and preg-
nancy outcome variables. Data items that were not specific to pregnancy were created
based on nationally endorsed metadata standards accessible through a metadata online
registry [18]. The data items are shown in Table 2.
Table 2. Final audit tool used.
Category Data Items
For all women
Patient ID, date of birth, date of referral, EDC, estimated EDC by ultrasound, ethnic
group, gestation at first review, gravidity, parity, height, pre-pregnancy weight,
booking weight, smoking status, chronic hypertension, gestational hypertension,
preeclampsia, delivery method, baby’s date of birth, gestational age at delivery, baby
sex, birth weight, APGAR at 5 mins, shoulder dystocia, other birth trauma, admission
to SCN/NICU, neonatal hypoglycaemia < 2.6 mmol/L, jaundice needing
phototherapy, minor congenital malformation, major congenital malformation,
breast feeding on discharge.
Women with GDM OGTT fasting, OGTT 1 h, OGTT 2 h, HbA1c at GDM diagnosis, GDM treatment.
Women with type 1 or type 2 diabetes
Planned pregnancy, OHA at conception, statin at conception, ACE/ARB at conception,
folate (1st trimester folate dose), aspirin use, retinopathy, nephropathy, hypoglycaemia
needing assistance, number of hypoglycaemic episodes needing assistance, eGFR,
urine ACR, HbA1c % trimester 1, HbA1c % trimester 2, HbA1c % trimester 3, type 1
diabetes treatment, type 2 diabetes treatment.
EDC = Estimated date of confinement; SCN = Special care nursery; NICU = Neonatal intensive care unit; OHA = Oral hypoglycaemic
agents; ACE = Angiotensin-converting enzyme inhibitors; ARB = Angiotensin II receptor blockers; eGFR= estimated glomerular filtration
rate, ACR = Albumin creatinine ratio, GDM = Gestational diabetes mellitus; OGTT = Oral glucose tolerance test.
2.3. Data Collection
This pilot was undertaken in a “double blind” (site and participant) fashion. Data
collection was coordinated by a trusted third party (TTP) process, where in this instance,
a “trusted” agent acts as a channel for communication ensuring that participating sites
remain anonymous to the benchmarking centre. Health services that volunteered to
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participate in the programme sent their existing locally approved data directly to the TTP
after obtaining approval based on local policies. Data were deidentified before being sent
to the benchmarking centre and were sent in a single Excel spreadsheet in standard format
as an email attachment. Data were checked for completeness and formatting, and further
queries were made to participating sites through the TTP for clarification as needed. All
questioned data items that sites could not validate were deleted. All records containing
births recorded as less than 28 weeks gestation were also deleted due to variations in data
collection between sites. We accepted validated heights as low as 140 cm and as high as
185 cm and a validated weight maximum of 185 kg to avoid including data entry errors.
The TTP created a unique identifier for each participating health service before disclosing
the data for analysis to the benchmarking centre. Additionally, sites were re-coded at the
central analysis site as an added security measure to preclude identification of any site
from the analyses.
2.4. Feedback Reports
Participating sites were provided with a feedback report describing clinical care in
their centre. The benchmarking report enabled them to compare their performance against
other participating sites and identify local service needs. Sites were able to identify only
their own data reports.
2.5. Statistical Analysis
Comparisons were made between sites, but not between types of diabetes in preg-
nancy because of the selective nature of the audits. Outcome and other measures were
reported based upon non-missing data. Sites having all data missing for a given variable
were excluded from analyses relating to that variable. For categorical data, if the sites had
reported only “Yes” values and the remaining cells were blank/missing, these were inter-
preted as “No”. Categorical variables were described using numbers and percentages and
Pearson’s Chi-squared test, where appropriate, were used to compare groups. Continuous
variables were described using mean ± standard deviation and compared using analysis
of variance. Analyses were performed using IBM SPSS Version 24.0. Armonk, NY: IBM
Corp. All tests are 2 tailed with p < 0.05 taken as significant. The ethics approval for this
project was granted by the Western Sydney University Human Research Ethics Committee
(HREC Approval Number: H13648).
3. Results
This pilot audit covered 10,144 patient records (GDM, n = 8696, T1D, n = 435, T2D,
n = 1013) from 11 diabetes services (public clinics within tertiary urban hospitals with
2000–9000 births annually (n = 9), private urban clinic (n = 1), rural health service (n = 1))
after excluding multiple pregnancies (n = 103); pregnancies affected by new-onset diabetes
after organ transplantation (n = 2) and maturity-onset diabetes of the young (n = 1); and
pregnancies that ended in miscarriages, termination of pregnancy or perinatal death (n = 59)
(Figure 1). The majority (7/11) of the participating sites were located in one Australian state
(Figure 1). Eight services provided data for women with GDM, seven services reported
data for T1D in pregnancy, and nine services reported data for T2D in pregnancy. Each site
provided 1–5 years of data.
3.1. Maternal Characteristics
Table 3 shows the maternal characteristics of the study population. The mean age of
the participants was 32.3 ± 5.5 years. The mean gravidity and parity across all sites were
2.9 ± 1.9 and 1.3 ± 1.4 respectively. The pre-pregnancy and booking weights were recorded
for 64% and 61% of the reported pregnancies, respectively. The mean self-reported pre-
pregnancy and booking weights were 74.7 ± 21.1 kg and 84.0 ± 23.5 kg, respectively. The
mean pre-pregnancy body mass index for women with GDM, T1D, and T2D was 28.1 ± 7.0,
26.0 ± 5.4, and 31.5 ± 7.1 kg/m2, respectively. Within centres reporting these variables,
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6.7% of the women documented having a history of hypertension and 9.1% reported
smoking during pregnancy. Ethnicity was reported for 93% of women with significant
variation in ethnic makeup across services. Most were European (33.1%), followed by
South Asian (20.8%), East/South East Asian (13.8%), Māori/Pacific (12.5%), and Middle
Eastern (8.1%). Aboriginal and Torres Strait Islander constituted 2.6% of women.
3.2. Gestational Diabetes Mellitus
Table 4 shows the missing data, number of participating services, the proportion or
mean with the benchmark measure and the range across sites reporting data. There was
substantial variation in gestation at first review, although the mean attendance was at
24.8 ± 7.2 weeks. Among women with GDM, diet alone was used in 39.4% (28.8–57.3%)
with significant variation in use of metformin alone (0.4–43.7%), metformin + insulin
(1.5–23.4%) and insulin therapy alone (4.1–95.6%) (all p < 0.001). Elective and emergency cae-
sarean delivery ranged from 3.6% to 23.7% and 3.5% to 21.2%, respectively (both p < 0.0001).
Preterm birth (28 to <37 weeks) ranged from 3.7% to 9.4% (p < 0.05), large-for-gestational-age
10.3–26.7% (p < 0.0001), small-for-gestational-age 0–11.9% (p < 0.0001), admission to special
care nursery 16.7–25.0% (p < 0.0001), neonatal hypoglycaemia (<2.6 mmol/L) 6.0–27.0%
(p < 0.0001), preeclampsia 2.0–5.2% (p < 0.0001), and shoulder dystocia 0–7.2% (p < 0.0001)
all varied significantly across services. There was no significant difference in breastfeeding
on discharge or jaundice requiring phototherapy. Major but not minor malformations
varied across sites.
3.3. Pre-Gestational Diabetes
3.3.1. Pre-Gestational Diabetes: Pregnancy Planning
Table 5 shows that for women with both T1D and T2D in pregnancy, recording
measures of pregnancy planning were limited. Where data were available, recorded uptake
varied significantly across services for women with pregestational diabetes including first
trimester higher dose folate ranging from 28.6% to 100%, pregnancy planning ranging from
14.3% to 87.5% and gestation at first attendance from three to 33 weeks gestation. Only
limited exposure (0.7–1.1%) was shown to statins and ACE inhibitors/angiotensin receptor
blockers at conception. Oral anti-hyperglycaemic agents, inclusive of metformin, which
was not reported separately, were in use at conception in 20.0–58.2% of women with T2D. A
major concern is the higher mean HbA1c at conception of 7.7 ± 1.6% (61 ± 17 mmol/mol)
and 7.3 ± 1.7% (56 ± 19 mmol/mol) among women with T1D and T2D, respectively.
Between 59.6% and 100% of women with TID and 0–58.3% of women with T2D had a
first trimester HbA1c > 6.5% (48 mmol/mol). However, these results exclude 10.6% of
women with T1D and 46.2% of women with T2D without a documented early HbA1c.
Complication screening ranged from 9.3% to 94.7% women having a first trimester urinary
albumin:creatinine ratio. Prevalences of documented retinopathy and nephropathy in
women with T1D ranged from 6.3% to 39.6% and 3.2–6.3%, respectively, and with T2D
0.7–7.9% and 5.3–20.0%, respectively.
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Table 3. Baseline characteristics of the study population (live singleton births only).
Characteristics N Mean ± SD or n (%) (Range) @ Range (N, Mean or %
Across All Sites)




N % Missing Range AcrossAll Sites
Number of women 10,144 – 59–2426 0 – –
GDM 8696 – 54–2397 0 – –
Type 1 diabetes 435 – 7–295 0 – –
Type 2 diabetes 1013 – 19–428 0 – –
Age (years) 10,114 32.3 ± 5.5(15–51) 31.0–35.1 0 30 0–11.9
Gravidity 10,065 2.9 ± 1.9(1–22) 2.4–3.3 0 79 0–8.9
Parity 10,066 1.3 ± 1.4(0–11) 0.8–1.6 0 78 0–16.9
Pre-pregnancy weight (kg) 6471 74.7 ± 21.1(34.0–185.0) 68.5–89.8 3 3673 0–100
Mean Pre-pregnancy BMI (kg/m2)
GDM 6060 28.1 ± 7.0(26.2–32.7) 26.2–32.7 5 2636 30.3
Type 1 diabetes 215 26.0 ± 5.4(22.8–30.7) 22.8–30.7 5 320 73.6
Type 2 diabetes 244 31.5 ± 7.1(29.9–38.6) 29.1–38.6 4 769 75.9
Booking weight (kg) 6191 84.0 ± 23.5(33.9–193.0) 71.3–88.6 4 3953 0–99.9
History of hypertension 296 6.7 1.9–12.9 2 5739 0–100
Smoking 566 9.1 2.3–15.1 2 3919 0–100
@ percentage of all possible values. † Sites missing 100% of data were removed from the denominator; For categorical data, if the sites had reported only “Yes” values and the remaining cells were blank/missing,
these were interpreted as “No”. BMI = Body mass index; GDM = Gestational Diabetes Mellitus.
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Table 4. Pregnancy care and obstetric outcomes of women with gestational diabetes mellitus.
Variables Mean ± SD or N/Total Available Data (%)@ Range Across Sites Number of Sites Missing 100% Data Missing Across Sites Reporting N/(%) †
Gestation at first review (weeks) 24.8 ± 7.2 22.1–26.7 *** 4 6195 (71.2)
Diet Only 2082/5278 (39.4) 28.8–57.3 ** 1 3418 (39.3)
Metformin use only 991/5278 (18.8) 0.4–43.7 ** 1 3418 (39.3)

















Gestational age at delivery (weeks) 38.6 ± 1.5 38.2–38.9 *** 0 174 (2.0)
Late preterm (34–37 weeks) 651/8696 (7.5) 3.7–9.4 * 0 174 (2.0)












LGA 754/5759 (13.1) 10.3–26.7 *** 2 2937 (33.8)
SGA 538/5759 (9.3) 0–11.9 *** 2 2937 (33.8)
Preeclampsia 110/3590 (3.1) 2.0–5.2 *** 2 5106 (58.7)
Shoulder dystocia 92/3321 (2.8) 0.0–7.2 *** 4 4629 (53.2)
Admission to SCN/NICU 710/3347 (21.2) 16.7–25.0 *** 3 5378 (61.8)
Neonatal hypoglycaemia <2.6 mmol/L 690/4079 (16.9) 6.0–27.0 *** 3 4599 (52.9)











Breast feeding on discharge 795/1273(62.5) 57.4–62.7 # 6 7279 (83.7)
@ Percentage of all possible values; † Sites missing 100% of data were removed from denominator; For categorical data, if the sites had reported only “Yes” values and the remaining cells were blank/missing,
these were interpreted as “No”. SCN = Special care nursery; NICU = Neonatal intensive care unit; LGA = Large for Gestational Age; SGA = Small for Gestational Age; p values refer to comparisons between sites;
# Nonsignificant; * p < 0.05; ** p < 0.001; *** p < 0.0001.
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Sites Reporting N/(%) †
N/(%)




Sites Reporting N/(%) †
Gestation at first
review (weeks) 9.1 ± 5.3 3–27 *** 4 343 (78.9) 11.1 ± 6.1 3.5–33 * 5 862 (85.1)
Pregnancy planning 65/101 (64.4) 14.3–87.5 *** 3 339 (77.9) 97/207 (46.9) 20.0–63.2 * 4 812 (80.2)
OHA/GLP1RA on
conception 1/94 (1.1) – 4 342 (78.6) 100/210 (47.6) 20.0–58.2 ** 5 824 (81.3)
Statin at conception 0/93 (0.0) – 4 342 (78.6) 1/152 (0.7) – 5 862 (85.1)
ACEI/ARB at conception 1/93 (1.1) – 4 342 (78.6) 1/152 (0.7) – 5 863 (85.2)
First trimester Folate (5 mg) 92/101 (91.1) 28.6–100 *** 3 335 (77.0) 178/207 (86.0) 57.9–100 *** 4 810 (80.0)
Retinopathy 77/428 (18.0) 6.3–39.6 ** 1 49 (11.3) 16/673 (2.4) 0.7–7.9 * 2 439 (43.3)
Nephropathy 21/428 (4.9) 3.2–6.3 # 1 40 (9.2) 95/991 (9.6) 5.3–20.0 *** 1 97 (9.6)
Urine ACR 145 (33.3) 26.4–86.8 # 290 (66.7) 196 (19.3) # 9.3–94.7 817 (80.7)
Aspirin use in pregnancy 215/428 (50.2) (13.2–59.0) *** 1 343 (78.9) 178/673 (26.4) (0–55.6) *** 2 862 (85.1)
Hypoglycaemia needing
assistance 0/45 (0.0) – 6 390 (89.7) 1/24 (4.2) – 7 989 (97.6)
HbA1c 1st trimester 7.7 ± 1.6 5–16.5 ** 2 46 (10.6) 7.3 ± 1.7 4.2–14.0 * 3 468 (46.2)
HbA1c 2nd trimester 6.6 ± 1.1 4.5–11.1 ** 1 321 (73.8) 6.1 ± 1.1 4.3–10.4 * 2 821 (81.0)
HbA1c 3rd trimester 6.8 ± 1.0 4.8–11.0 * 1 44 (10.1) 6.3 ± 1.1 4.0–12.6 ** 2 411 (40.6)
HbA1c 1st trimester >6.5%
(48mmol/mol) 78.4 59.6–100 * 2 46 (10.6) 54.6 0–58.3 ** 3 469 (46.3)
HbA1c 2nd trimester >6.0%
(42 mmol/mol) 69.9 50.0–82.4 # 1 322 (74.0) 41.7 5.9–62.5 # 2 821 (81.0)
HbA1c 3rd trimester >6.0%
(42 mmol/mol) 77.2 50.0–88.6 # 1 45 (10.3) 48.5 12.5–100 * 2 411 (40.6
Diet Only – – – – 3/568 (0.5) 0–0.5 1 445 (43.9)
Metformin use only – – – – 158/568 (27.8) 0–100 1 445 (43.9)
Insulin use only – – – – 132/568 (23.2) 0–100 1 445 (43.9)
Metformin and Insulin use – – – – 275/568 (48.4) 0–79.9 1 445 (43.9)






























Sites Reporting N/(%) †
N/(%)




Sites Reporting N/(%) †
Gestational age at
delivery (weeks) 36.4 ± 1.7 28.1–40.2* 0 1 (0.2) 37.3 ± 1.8 27.3–41.3 *** 0 12 (1.2)
Late preterm (34–37 weeks) 208/435 (47.9) 7.5–52.1 * 0 1 (0.2) 227/1013 (22.4) 13.6–31.6 * 0 12 (1.2)
Very preterm/moderately




















LGA 70/112 (62.5) 20.0–85.7 # 1 323 (74.3) 58/225 (25.8) 15.8–33.3 # 2 788 (77.8)
SGA 5/112 (4.5) 0–16.7 # 1 323 (74.3) 29/225 (12.9) 0–20.0 # 2 788 (77.8)
Preeclampsia 76/425 (17.9) 14.9–28.6# 0 10 (2.3) 74/681 (10.9) 5.0–33.3* 1 332 (32.8)
Shoulder dystocia 2/102 (2.0) 0–3.1 # 2 336 (77.2) 1/158 (0.6) - 3 860 (84.9)
Admission to SCN/NICU 279/428 (65.2) 12.5–100 *** 1 14 (3.2) 273/676 (40.4) 21.8–50.0 * 2 362 (35.7)
Neonatal hypoglycaemia
<2.6 mmol/L 232/435 (53.3) 12.5–87.5 *** 0 24 (5.5) 227/695 (32.7) 10.5–52.6 ** 1 390 (38.5)
Jaundice needing





















Breast feeding on discharge 98/125(78.4) 57.1–93.8 * 3 313 (72.0) 141/190 (74.2) 20.0–89.5 * 4 831 (82.0)
@ Percentage of all possible values; † Sites missing 100% of data were removed from the denominator; For categorical data, if the sites had reported only “Yes” values and the remaining cells were blank/missing,
these were interpreted as “No”. OHA = Oral hypoglycaemic agents including metformin; ACEI= Angiotensin converting enzyme inhibitors; ARB = Angiotensin receptor blockers; ACR = Albumin creatinine
ratio; SCN = Special care nursery; NICU = Neonatal intensive care unit; LGA = Large for Gestational Age; SGA = Small for Gestational Age. p values refer to comparisons between sites within type of diabetes;
# Nonsignificant; * p < 0.05; ** p < 0.001; *** p < 0.0001.
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Figure 1. Flow chart of site selection process. ADIPS = Australasian Diabetes in Pregnancy Society; NSW = New South
Wales, VIC = Victoria, NZ = New Zealand, WA = Western Australia; TAS = Tasmania, HREC = Human Research Ethics
Committee; QLD = Queensland, NT = Northern Territory, ACT = Australian Capital Territory.
3.3.2. Pre-Gestational Diabetes: Antenatal Management
The mean recorded gestational week at first visit to the participating diabetes service
was beyond the recommended eight weeks of gestation [17] for women with both T1D and
T2D (9.1 ± 5.3 and 11.1 ± 6.1 weeks respectively). The documentation of hypoglycaemia
needing assistance was limited for all women with known diabetes (<5%). The HbA1c
testing in the second trimester was limited at 26.2% (T1D) and 19% (T2D), although 89.9%
and 59.4% respectively were completed in the third trimester. The HbA1c in the third
trimester remained above target in >6.0% (42 mmol/mol) among most women with T1D
(range 50.0–88.6%) and just under 50% of women with T2D (range 12.5–100%). Metformin
use varied between 0 and 100% in women with T2D, while insulin pump use in women
with T1D varied between 0 and 68% among reporting sites. Aspirin use for preeclampsia
prophylaxis ranged between 0% and 59.0% across all women.
3.3.3. Pre-Gestational Diabetes: Pregnancy Outcomes
Variable recording of birth outcomes occurred. While birth weight was available
for 98.2% of infants, recording of several important neonatal outcomes was low. The
reporting of malformations was limited, particularly among pregnancies complicated by
T2D such that interpretation was difficult. Where recorded, rates of major pregnancy
complications were high for women with both T1D and T2D. Elective caesarean rates
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ranged from 12.5–45.8% and emergency caesarean from 17.4% to 57.7% in T1D, and 0–73.7%
and 0–48.3% in T2D. Gestational age at delivery was well recorded with marked variation in
the prematurity rates (<37 weeks) of 7.5–52.1% in T1D and 13.6–31.6% in T2D (both p < 0.05),
while birthweight ≥4000 g ranged from 14.3% to 37.5% and 0–23.6% respectively. LGA
reporting was limited due to missing variables for the centile calculator (e.g., ethnicity). T1D
data were relatively complete and showed significant variation in neonatal hypoglycaemia
(12.5–87.5%) and admission to special care nursery (12.5–100%) (both p < 0.001).
4. Discussion
This pilot multi-centre audit involved the collection of de-identified data, testing
of the internal governance process and benchmarking, and reporting of pregnancy care
data from eleven volunteer diabetes health services across Australia and New Zealand.
Our comparative analyses showed significant variation in diabetes care and pregnancy
outcomes among services for women with GDM, T1D, and T2D. The reporting of pre-
conception and antenatal care was limited for women with GDM and pre-existing diabetes,
particularly for those with T2D. A large number of missing data items indicated variability
between individual audits, lack of real time collection tools and absence of agreed indicators
for measuring quality of care.
For women with GDM, these 2020 results are roughly comparable to those from
2003 [14] including the gestation at birth (39 weeks), birthweight <2000 g (6% vs. 5%),
elective caesarean section (12%) and shoulder dystocia (3%), with some possible reductions
in birthweight ≥4000 g (9.6% vs. 14%), neonatal hypoglycaemia (16.9% vs. 20%), and
emergency caesarean section (9.5% vs. 12%). However, the large variation in care and birth
outcomes has continued. Since that first audit, the process for screening and diagnosing
GDM has changed [19], new management approaches have been adopted in some services
including metformin therapy, and a range of different models of care have been evolv-
ing [20]. It is possible that some sites missed women, particularly with diet-managed GDM,
because they remained under general obstetric and/or private care and did not receive any
local diabetes service support.
For women with pregestational diabetes, since the initial ADIPS benchmarking pro-
gram in 2003 and a subsequent audit in 2004 across 10 Australian teaching hospitals, some
aspects of care have probably improved [12,21], e.g., pre-pregnancy counselling and folate
supplementation. However, while 31% (T1D) and 39% (T2D) had a caesarean delivery
in the 2003 audit, and 63% had caesarean deliveries in the 2004 audit, >50% (T1D) and
~27% (T2D) had caesarean deliveries in the current audit. First trimester HbA1c may
have improved in T2D but not T1D, with HbA1c 7.6% (60 mmol/mol) (T1D) and 7.8%
(62 mmol/mol) (T2D) respectively in 2003, 7.1% (54 mmol/mol) overall in 2004 but 7.7%
(61 mmol/mol) (T1D) and 7.3% (56 mmol/mol) (T2D) currently. Of additional concern is
no apparent change in neonatal hypoglycaemia over this time with rates of 48% (T1D) and
30% (T2D) in 2003 compared to 53.3% (T1D) and 32.7% (T2D) now. Such limited changes
also occurred in the national audit reported recently from the UK [11], which recommended
health system changes to improve pre-pregnancy planning and antenatal care for women
with pre-gestational diabetes [11,12]. One possible trend (depending on ascertainment) of
interest is the increasing number of women with T2D: 49% in the first ADIPS audit, 55% in
the 2004 audit, and currently accounting for 70% of women with pregestational diabetes.
The main challenge encountered during the implementation of this audit was the
lengthy and complicated ethics approval process at some locations, which prevented
several services from participating in the audit. Some services had to obtain state-based
approval for accessing data and transferring them interstate. Some services had Aboriginal
community-controlled organisations as partners and required approval from an indigenous
reference group, which was not feasible within the timelines and governance processes
of this audit. Obtaining such approval appropriately is obviously crucial in ensuring the
trust of both health care providers and communities/patients in these areas. Coordinat-
ing the multiple layers of governance however made the audit process time consuming
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and complicated, but provided lessons for any future, sustainable widespread audit and
benchmarking programme.
Although the audit tool provided useful information on antenatal care, problems were
encountered when collating birth data. Endocrinologists/stand-alone diabetes services in
close contact with women during their prenatal period held detailed pre-pregnancy care
data but could not provide information following transfer of care to an antenatal service.
Similarly, diabetes services are not necessarily integrated with antenatal care.
Mismatches occurred between the variables listed in the audit tool and those that had
already been collected by the participating services. Some had defined ethnicity based
on the country-of-birth criteria and others reported only major ethnic groups, ignoring
noticeable heterogeneity within each major group. For example, New Zealand but not
Australian sites separated Māori and Pacific women while others did not separate East
Asian and South East Asian women. This lack of consistency in ethnicity data coding
made ethnicity classification difficult. Similarly, gestational hypertension and chronic
hypertension were grouped into one category for some women when the service initially
collected the data. For monitoring proteinuria, some services had measured urine protein
to creatinine ratio more often than urine ACR especially in late pregnancy, but the PCR data
were not included in the audit. Regarding data fields for the estimated date of confinement
(EDC), the majority of sites reported initial EDC based on last menstrual period with a
few sites basing EDC on dating US scan, however the data many have been collected by
the antenatal clinic- indicating work needed in aligning communication/documentation
between stand-alone diabetes and associated antenatal services. Significantly, data on
hypoglycaemia needing assistance were missing for all services except one centre, and
none of the services reported data for the number of hypoglycaemic episodes: it is unclear
whether this was due to missing or data or that these events are now very rare. The high
rates of congenital anomalies in these live births (with miscarriages and fetal loss excluded)
suggest major malformation rates would be higher reinforcing the need for preconception
care for women with known diabetes. A recent meta-analysis showed a 70% reduction
in congenital malformation in women who received preconception care [22]. The large
proportion of missing data on congenital malformation is another concern. Further, the
current numbers may be incomplete because data on late-onset malformations are only
available later in infancy. Some services offered aggregate data (i.e., summaries of the data
they hold) and this was excluded in the audit but may need to be an option in the future.
The current audit tool may require refinement in the future to separate some ethnic
groups explicitly (e.g., Māori and Pacific) and metformin from other diabetes treatments at
conception. Access to pre-pregnancy clinics [12] and the recent introduction of continuous
glucose monitoring are also activities that need to be included to evaluate associations
with outcomes and variation in use. However, one of the challenges of these audits is
that data entry is time consuming, particularly if data is held in multiple locations and
most centres rely on clinicians who already have heavy clinic loads to update the database.
While it is desirable to collect as many important variables as possible, this has to be
balanced against the feasibility at the various centres in terms of human resources. The
data set will be reviewed before the next audit round to decide which need to be dropped,
refined or added. Methods for data transfer (e.g., using services such as CloudStor) are
also under review for sending de-identified data. Ideally, the data are entered into a system
where the centre has ongoing access to reports and can share them between antenatal and
diabetes services. Such a system will implement measures to harmonize data collection and
validation processes among health services. Birth centre discharge summary forms could
be updated to include such audit data which could be and sent to nominated diabetes care
providers in addition to general practitioners.
The major strength of this study is that it is the largest national benchmarking audit of
diabetes in pregnancy services across Australia and New Zealand. Diabetes services with a
range of characteristics in major metropolitan cities in Australia and New Zealand as well
as in rural and private care settings were included. A major limitation of the audit is the lack
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of data on pregnancies ending before 28 weeks gestation including miscarriage, stillbirth
or induced abortion and the audit will underestimate the proportion of pregnancies with
some adverse outcomes (e.g., malformations, pre-eclampsia) as a result. These data should
be collected comprehensively in future audits. Another limitation was a difficulty defining
a denominator in some analyses due to missing/uncoded data. There was some variation
in GDM diagnosis: the study population included women with GDM diagnosed based on
ADIPS 2014 [23], ADIPS 1998 [24], and New Zealand GDM criteria [25]. Further limitations
were that these were voluntary sites and they may not be representative of services across
Australia and New Zealand (as evidenced by relatively low proportion of women of
European descent compared with national data). Similarly, as in 2003 and 2004, the audits
were from a limited number of sites with modest numbers of patients with different sites
in each audit. Nonetheless the findings do illustrate the usefulness of periodic voluntary
auditing as it gives an indication of changes over time. The considerable variation between
sites in some outcomes may be caused partly by the differences in population characteristics
that they serve, and no attempt has been made to assess for population differences as we
did not want to potentially identify sites by presenting data on ethnic background or
diagnostic blood glucose data. Further, individual outcomes will be influenced by the
completeness of the data submitted for analysis. Missing data may reflect the fact that a
particular field or fields is/are not recorded in the database, and not necessarily that they
are not part of patient care.
5. Conclusions
Our national pilot audit provides information on how quality indicators in perinatal
diabetes care have been followed and documented by diabetes services for women with pre-
existing diabetes and GDM. Although the benchmarking report across sites is not shown in
this paper, our findings indicate an under-recording of the diabetes care provided to these
women and evidence that improvement in care is needed even among these volunteer sites
with a major interest in optimising pregnancy outcomes. There is a particular need for
targeted and improved pregnancy preparation for women with T2D. As quality perinatal
care is integral for the survival and well-being of the fetus, an ongoing national audit is
necessary to improve pregnancy care for women affected by hyperglycaemia according
to the standards set by the ADIPS. This preliminary, and essentially exploratory audit,
highlights that a national clinical audit with defined and regulated outcomes, is feasible
and urgently needed with communication between both maternity and diabetes services.
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